Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | MITF | O75030 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.53 |
| ▸ | HCAR2 | Q8TDS4 | 7/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4201086 | 0.88 | TP53 (0.57) | LMNAATMMITFTP53NCOA3 | |
| SCHEMBL10312532 | 0.83 | MITF (0.54) | LMNAATMMITFTP53NCOA3 | |
| SCHEMBL13781596 | 0.81 | HCAR2 (0.65) | LMNAATMMITFTP53NCOA3 | |
| SCHEMBL4548481 | 0.80 | HCAR2 (0.62) | LMNAATMMITFTP53NCOA3 | |
| SCHEMBL4192570 | 0.80 | TSHR (0.53) | LMNAATMMITFTP53NCOA3 | |
| SCHEMBL1568004 | 0.79 | LMNA (0.65) | LMNAATMMITFTP53NCOA3 | |
| SCHEMBL4556040 | 0.77 | HCAR2 (0.61) | HCAR2CYP2C9 | |
| SCHEMBL10312533 | 0.77 | MAPT (0.48) | LMNAATMHCAR2CYP2C9TSHR | |
| SCHEMBL4548484 | 0.76 | HCAR2 (0.58) | LMNAATMHCAR2CYP2C9ALDH1A1 | |
| SCHEMBL1483898 | 0.76 | HCAR2 (0.52) | LMNAMITFTP53NCOA3HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101437796-A | Piperidine derivatives, their process for preparation, their use as therapeutic agents and pharmaceutical compositions containing them | ASTRAZENECA AB (SE) | 2009-05-20 | — | — | CN | disclosed |
| US-20090012125-A1 | Piperidine Derivatives, Their Process for Preparation, Their Use as Therapeutic Agents and Pharmaceutical Compositions Containing Them | CAGE PETER | 2009-01-08 | — | — | US | disclosed |
| EP-1996551-A2 | PIPERIDINE DERIVATIVES, THEIR PROCESS FOR PREPARATION, THEIR USE AS THERAPEUTIC AGENTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | AstraZeneca AB (SE) | 2008-12-03 | — | — | EP | disclosed |
| WO-2007102769-A2 | PIPERIDINE DERIVATIVES, THEIR PROCESS FOR PREPARATION, THEIR USE AS THERAPEUTIC AGENTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ASTRAZENECA AB (SE) | 2007-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012125-A1 | Piperidine Derivatives, Their Process for Preparation, Their Use as Therapeutic Agents and Pharmaceutical Compositions Containing Them | CCR3, CCR1, CCR5 | LMNA 3005/4885ATM 4251/4885MITF 1948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.